Dermatologic Manifestations of Pellagra Medication

  • Author: Vladimir Hegyi, MD, PhD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: May 15, 2012
 

Medication Summary

The goals of pharmacotherapy are to correct vitamin deficiency, prevent complications, and reduce morbidity.

Next

Vitamins

Class Summary

Exogenous administration cures the syndrome and, within the levels prescribed, niacin use is not associated with the uncomfortable flushing observed in other conditions (eg, hypercholesterolemia). Niacinamide (nicotinamide) is usually tolerated better than nicotinic acid, and it is the preferred agent because it does not precipitate the flushing, itching, and burning observed after the ingestion of large doses of niacin.

View full drug information

Niacin (Vitamin B-3)

 

Used in tissue respiration, lipid metabolism, and glycogenolysis.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Vladimir Hegyi, MD, PhD  Associate Professor, Department of Pediatric Dermatovenereology, School of Medicine, Comenius University, Bratislava

Vladimir Hegyi, MD, PhD is a member of the following medical societies: European Academy of Dermatology and Venereology, European Dermatology Forum, and Slovak Dermatovenereological Society

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

James Fulton Jr, MD, PhD  Center for Cosmetic Dermatology; Consultant, Vivant Pharmaceuticals, LLC

James Fulton Jr, MD, PhD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American Society for Laser Medicine and Surgery, Dermatology Foundation, International Society of Cosmetic and Laser Surgeons, and Skin Cancer Foundation

Disclosure: Vivant Pharmaceuticals Grant/research funds Consulting

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD  Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Professors of Dermatology, North American Hair Research Society, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. Jan 2004;43(1):1-5. [Medline].

  2. Rajakumar K. Pellagra in the United States: a historical perspective. South Med J. Mar 2000;93(3):272-7. [Medline].

  3. Rille JH. Medizinische Gesellchaft Leipzig. Sitzug vom 16. November 1926. Ueber Pellegra (mit Lichtbildern). Dermatol Wochenschrift. 1927;6:189.

  4. Elvehjem CA, Madden RJ, Strong FM, Woolley DW. Relation of nicotinic acid and nicotinic acid amide to canine black tongue. J Am Chem Soc. 1937;59:1767-68.

  5. Murray MF. Niacin as a potential AIDS preventive factor. Med Hypotheses. Nov 1999;53(5):375-9. [Medline].

  6. Murray MF, Langan M, MacGregor RR. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition. Jul-Aug 2001;17(7-8):654-6. [Medline].

  7. Pitche P, Kombate K, Tchangai-Walla K. [Prevalence of HIV infection in patients with pellagra and pellagra- like erythemas]. Med Trop (Mars). 1999;59(4):365-7. [Medline].

  8. Ladoyanni E, Cheung ST, North J, Tan CY. Pellagra occurring in a patient with atopic dermatitis and food allergy. J Eur Acad Dermatol Venereol. Mar 2007;21(3):394-6. [Medline].

  9. Kertesz SG. Pellagra in 2 homeless men. Mayo Clin Proc. Mar 2001;76(3):315-8. [Medline].

  10. Lorentzen HF, Fugleholm AM, Weismann K. [Zinc deficiency and pellagra in alcohol abuse]. Ugeskr Laeger. Dec 11 2000;162(50):6854-6. [Medline].

  11. Lu JY, Yu CL, Wu MZ. Pellagra in an immunocompetent patient with cytomegalovirus colitis. Am J Gastroenterol. Mar 2001;96(3):932-4. [Medline].

  12. Baquet S, Wuillaume F, Van Egmond K, Ibanez F. Pellagra outbreak in Kuito, Angola. Lancet. May 20 2000;355(9217):1829-30. [Medline].

  13. Stratigos JD, Katsambas A. Pellagra: a still existing disease. Br J Dermatol. Jan 1977;96(1):99-106. [Medline].

  14. Oztürk F, Koca R, Aydin M, Cantürk MT, Akpolat I, Küçüködük S. Pellagra: a sporadic pediatric case with a full triad of symptoms. Cutis. Jul 2001;68(1):31-4. [Medline].

  15. Isaac S. The "gauntlet" of pellagra. Int J Dermatol. Aug 1998;37(8):599. [Medline].

  16. Karthikeyan K, Thappa DM. Pellagra and skin. Int J Dermatol. Aug 2002;41(8):476-81. [Medline].

  17. Stratigos AJ, Antoniou C, Papathanakou E, Daboudi M, Tranaka K, Tsara K, et al. Spectrum of idiopathic photodermatoses in a Mediterranean country. Int J Dermatol. Jun 2003;42(6):449-54. [Medline].

  18. Brown TM. Pellagra: an old enemy of timeless importance. Psychosomatics. 2010;51(2):93-97. [Full Text].

  19. Kapas I, Majtenyi K, Törö K, Keller E, Voigtländer T, Kovacs GG. Pellagra encephalopathy as a differential diagnosis for Creutzfeldt-Jakob disease. Metab Brain Dis. Jun 2012;27(2):231-5. [Medline].

  20. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. Oct 2005;100(10):2307-14. [Medline].

  21. Nogueira A, Duarte AF, Magina S, Azevedo F. Pellagra associated with esophageal carcinoma and alcoholism. Dermatol Online J. 2009;15(5):8. [Full Text].

  22. Reichman O, Sobel JD. Vulvovaginal pellagra and lichen sclerosus complicating carcinoid syndrome. Obstet Gynecol. 2009;113(2 Pt 2):543-545. [Full Text].

  23. Kaimal S, Thappa DM. Diet in dermatology: revisited. Indian J Dermatol Venereol Leprol. Mar-Apr 2010;76(2):103-15. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.